3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
141
Neoplasm Metastasis
6
Neoplasms
4
Prostate Adenocarcinoma
2
Osteoporosis
2
Hirsutism
2
Thrombocytosis
1
Stage I Prostate Adenocarcinoma AJCC v7
1
Stage I Prostate Adenocarcinoma
1
Sexual Dysfunction, Physiological
1
Recurrence
1
Primary Myelofibrosis
1
Primary Dysautonomias
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
PSA Level Greater Than Two
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Non Castrate Metastatic Prostate Cancer
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lower Urinary Tract Symptoms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Leukemia, Myeloid, Accelerated Phase
1
Interventions
enzalutamide
1
bicalutamide
1
Receptors, Androgen
1
Leuprolide
1
Goserelin
1
Flutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Primary Dysautonomias
×
bicalutamide
×
Genitourinary
×
Clear all
NCT05700903
2026-03-02
ARCH
University of Colorado, Denver
Phase 4
Completed
10 enrolled